Collectively, our findings reveal a new mechanism of CTC–neutrophil cluster formation via ICAM-1-suPAR-CD11b axis-mediated tumor cell and neutrophil binding, which could represent new therapeutic targets for treating metastatic TNBC. This evidence concerns the gene ICAM1 and neoplasm.